Amgen (AMGN) Tops Q2 EPS by 41c, Issues In-Line Guidance

Amgen (NASDAQ: AMGN) reported Q2 EPS of $4.25, $0.41 better than the analyst estimate of $3.84. Revenue for the quarter came in at $6.2 billion versus the consensus estimate of $6.18 billion.

GUIDANCE:

Amgen sees FY2020 EPS of $15.10-$15.75, versus the consensus of $15.64. Amgen sees FY2020 revenue of $25-25.6 billion, versus the consensus of $25.45 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Sherwin-Williams climbs 18% off 52-week low as Citi sets $380 target
• CareDx completes $171.2M sale of lab products unit to Eurobio Scientific